



# CKD vs AKI – So many markers, so little time, so much confusion!

Aimi Kato BVMS MRCVS

IDEXX Professional Services Veterinarian

21.03.2025

**IDEXX**

**Disclosure:**  
Full-time Employee of IDEXX



The information contained herein is intended to provide general guidance only. As with any diagnosis or treatment you should use clinical discretion with each patient based on a complete evaluation of the patient, including history, physical exam and presentation, and laboratory data. With respect to any drug therapy or monitoring program, you should refer to applicable product insert(s) for complete description of dosage, indications, interactions, and cautions. Diagnosis, treatment, and monitoring should be patient specific and is the responsibility of the veterinarian providing primary care. (2024)

# Learning outcomes

## 01 What is the function of kidneys?

- + Recall the role the kidneys play in overall health

## 02 How do we assess kidney health?


- + Describe the different biomarkers for glomerular filtration rate (GFR) and what they tell us

## 03 What is kidney disease?

- + Recognise the difference between acute kidney injury (AKI) and chronic kidney disease (CKD)
- + Review IRIS CKD guidelines and the utility of FGF-23
- + Describe the AKI and CKD continuum
- + Discuss kidney injury and the value of cystatin B

## 04 How has our understanding of kidney health evolved?

- + Recognise the importance of staging and managing changes in kidney function




# Timeline of kidney biomarkers




## Proteinuria

Described by Hippocrates  
400 B.C.




## Creatinine

Jaffe reaction  
1886




## Glomerular filtration rate

Cockcroft-Gault equation  
for estimating GFR in 1973



## SDMA

Validated for  
use in dogs  
2015



## FGF-23

Launched for  
felines with  
chronic kidney  
disease  
2022



## Urinary cystatin B


Detects both  
active and  
acute kidney  
damage

Launched  
December 2023

# Function of the kidneys

## Key responsibilities:

- + Fluid balance in the body
  - + Blood pressure
  - + Hydration
- + Electrolyte balance in the blood
  - + Integral to cellular and organ function
- + Removal of nitrogenous waste
  - + Ammonia and urea
- + Excretion of drugs
- + Production of erythropoietin
  - + Stimulates red blood cell production



# Comorbidities or disease states can heavily impact kidney health



## Heart disease

Cardiorenal or  
renocardial  
syndrome

NT-proBNP  
Troponin  
SDMA



## Liver disease

Hepatic disease,  
congestion

CRP  
Iron



## Gastrointestinal disease

Inflammatory effect,  
hypoproteinemia

CRP  
Microbiome



## Endocrinopathy

Hormone  
imbalance,  
catabolic state

Aldosterone  
PTH  
Vitamin D  
Iron



## Infectious

Inflammatory/  
immune  
(acute or chronic)

Regional infectious  
disease testing  
Leishmaniasis  
Ehrlichiosis  
Lyme disease

How do we measure  
kidney health?



# Diagnosing kidney disease is more than diagnostics



## Physical exam

Kidney palpation  
Muscle mass  
Cardiac auscultation



## Medical history

Appetite/weight loss  
Energy  
Water consumption



## Diagnostics: lab work

Chemistry  
CBC  
Urinalysis




## Imaging

Radiographs  
Ultrasound

**Clinical decision points**




# Where is the problem?



# Function versus injury

## Functional markers

- + Reflect **GFR**
  - + **SDMA**
  - + **Creatinine**
  - + Urea
- + Measured in serum or plasma
- + **May not change with injury**



## Injury markers

- + Indicate **damage**
- + Usually **proximal tubules**
- + Tubules are the most metabolically active segment of the kidney
- + May increase before or without functional marker change
- + Measured in urine

# Anatomy of a nephron

- + Glomerulus

- + Filtration

- + Water

- + Small solutes

- + Proximal convoluted tubule

- + Resorbs 60%–65% of filtrate

- + Secretes cations, anions, H<sup>+</sup>

- + Loop of Henle

- + Produces ultrafiltrate

- + Distal tubule

- + Collecting tubule

- + Collecting duct

- + Electrolyte balance

- + Acid-base balance

- + Water resorption




Image: RMack Biorender

# How do we assess kidney function?

## Glomerular filtration rate (GFR)




Gold standard
















Expensive



Rarely done in practice



# GFR Biomarkers

  IDEXX SDMA <a href="#">Learn More</a>	<sup>a</sup> 12	0 - 14 µg/dL	
  Creatinine	1.3	0.9 - 2.3 mg/dL	
  BUN	34	16 - 37 mg/dL	
 BUN: Creatinine Ratio	26.2		
  Phosphorus	4.5	2.9 - 6.3 mg/dL	

## The biochemistry panel

### BUN

- + Late marker—up to 75% loss of function before changes noted
- + Impacted by other factors including diet and liver disease

### Creatinine

- + Late marker—up to 75% loss of function<sup>4</sup> before changes noted
- + Impacted by other factors, including muscle mass<sup>2,4</sup>

### SDMA


- + **Earlier marker**—SDMA increases on average with a 40% loss and as little as 25% loss of kidney function versus creatinine, which does not increase until 75% of kidney function.<sup>1-3</sup>
- + Not impacted by diet, muscle mass, liver disease

#### References

- Hall JA, Yerramilli M, Obare E, Yerramilli M, Yu S, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in healthy geriatric cats fed reduced protein foods enriched with fish oil, L-carnitine, and medium-chain triglycerides. *Vet J*. 2014;202(3):588–596. doi:10.1016/j.tvjl.2014.10.021
- Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. *J Vet Intern Med*. 2016;30(3):794–802. doi:10.1111/jvim.12835
- Nabity MB, Lees GE, Boggess MM, et al. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney disease in dogs. *J Vet Intern Med*. 2015;29(4):1036–1044. doi:10.1111/jvim.12835
- Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. *J Vet Intern Med*. 2014;28(6):1676–1683.

# Urinalysis

Collection	Free Catch
Color	Pale Yellow
Clarity	Slightly Cloudy
Specific Gravity	1,026
White Blood Cells	3 /HPF
Red Blood Cells	5 /HPF
Bacteria, Cocci	None Detected
Bacteria, Rods	None Detected
Squamous Epithelial Cells	<1 /HPF
Non-Squamous Epithelial Cells	1-2 /HPF
Hyaline Casts	None Detected
Urine Creatinine	50.3 mg/dL
Urine Protein	198.8 mg/dL
Urine Protein: Creatinine Ratio	4.0
Color	<sup>e</sup> Yellow




## Urine analysis

- Evaluates many aspects of renal function including glomerular, tubular, endocrine, fluid balance, and acid-base functions
- Includes Urine specific gravity (USG), Chemical analysis (glucose, ketones, pH), and Sediment evaluation (manual or automated)
- Affected by other factors, including endocrine disease and lower urinary tract disease

## Urine protein:creatinine ratio (UPC)

- Evaluates glomerular filtration barrier health and renal tubular function
- May increase **earlier** than Creatinine, Urea or SDMA or be the **only** abnormality in some types of renal dysfunction
- Required by IRIS for substaging and monitoring **all** dogs and cats with CKD

# Kidney function: creatinine versus GFR



Graph used with permission from Dr. Sheri Ross.

**Source:** Braun JP, Lefebvre HP, Watson ADJ. Creatinine in the dog: a review. *Vet Clin Pathol.* 2003;32(4):162–179. doi:10.1111/j.1939-165x.2003.tb00332.x

# How to interpret SDMA with creatinine

- + SDMA should always be interpreted along with creatinine and urinalysis.
- + Diagnostic algorithms and interpretive comments promote complete kidney evaluation.


SDMA	Creatinine		
N	N	=	No kidney disease
↑	N	=	Early kidney disease Poor body condition
N	↑	=	Possible kidney disease Highly muscled
↑	↑	=	Decreased GFR: potential kidney disease



# The importance of monitoring results

## Establish a baseline:

- + Allows for personalised care
- + Informs decisions in a crisis
  - + Preanaesthetic choice
  - + Fluid rate
  - + Post-op pain management
- + Guides decision-making as pet ages
  - + NSAIDs for degenerative joint disease?
  - + Diet change?



What is kidney disease?



# What is kidney disease?

## Active kidney injury (AKI) Potentially reversible

Ongoing kidney injury

### Caused by:

- + Toxin exposure
- + Nephrotoxic drugs
- + Infectious diseases, such as leptospirosis in dogs
- + Dehydration
- + High blood pressure


## Chronic kidney disease (CKD) Irreversible

### Caused by:


- + Kidney infections
- + Kidney and ureteral stones
- + Toxin ingestion
- + Infectious diseases, such as Lyme disease in dogs
- + Hereditary conditions

# Acute kidney event and chronic disease continuum


### Multiple small acute kidney injuries




### Multiple larger acute kidney injuries



### Sustained injury, ongoing



### Single severe injury




# Chronic kidney disease

## Early CKD symptoms are often nonspecific

- + Decreased appetite
- + Weight loss
- + Decreased activity level
- + Vomiting
- + Lethargy

## Symptoms in later stages may include the following

- + Drinking and urinating a lot
- + Loss of appetite
- + Vomiting
- + Bad breath
- + Oral ulcers
- + Marked weight loss



**Pet owners may not recognise subtle changes**




# Kidney disease is common in both dogs and cats

- + Chronic kidney disease is a **leading cause of suffering** in both dogs and cats.<sup>1</sup>
- + Prevalence increases with age.<sup>2</sup>
  - + With pets living longer, uncovering disease earlier can improve quality and lifespan.
- + Including SDMA in every chemistry profile **can improve outcomes** for your patients.

## References

1. Lulich JP, Osborne CA, O'Brien TD, Polzin DJ. Feline renal failure: questions, answers, questions. *Compend Contin Educ Pract Vet.* 1992;14(2):127–153.
2. Brown CA, Elliott J, Schmiedt CW, Brown SA. Chronic kidney disease in aged cats: clinical features, morphology, and proposed pathogenesis. *Vet Pathol.* 2016;53(2):309–326. doi:10.1177/0300985815622975
3. Brown SA. Renal dysfunction in small animals. The Merck Veterinary Manual website. [www.merckvetmanual.com/mvm/urinary\\_system/noninfectious\\_diseases\\_of\\_the\\_urinary\\_system\\_in\\_small\\_animals/renal\\_dysfunction\\_in\\_small\\_animals.html](http://www.merckvetmanual.com/mvm/urinary_system/noninfectious_diseases_of_the_urinary_system_in_small_animals/renal_dysfunction_in_small_animals.html). Updated October 2013. Accessed December 6, 2024.



In time, at least **1 in 3 cats<sup>1</sup>** and **1 in 10 dogs<sup>3</sup>** will develop kidney disease.


Chronic kidney disease




# To diagnose IRIS CKD Stage 1 and early IRIS CKD Stage 2

## One or more of these diagnostic findings

1



Creatinine increasing within the reference interval when no prerenal cause is apparent



SDMA increasing within the reference interval where no prerenal cause is apparent

2

**Persistent increased SDMA\* > 14 µg/dL**


\*SDMA = IDEXX SDMA® Test result

### Reference

International Renal Interest Society (IRIS). IRIS Staging of CKD. IRIS website. [www.iris-kidney.com/guidelines/staging.html](http://www.iris-kidney.com/guidelines/staging.html). Accessed December 6, 2024.

3

**Abnormal kidney imaging**




4

**Persistent renal proteinuria**

Urine protein to creatinine (UPC) ratio

- > 0.5 in dogs
- > 0.4 in cats





# To diagnose more advanced CKD (late IRIS CKD Stage 2–4)

## Both of these diagnostic findings

**Increased creatinine and SDMA concentrations**


CREATININE



SDMA



Results of both tests should be interpreted in light of a patient's hydration status.



Urine specific gravity  
**< 1.030**



Urine specific gravity  
**< 1.035\***




1.030	Canine	1.008
1.035	Feline	1.008

\*Some cats can produce hypersthenuric urine in the face of renal azotemia.

### Reference

International Renal Interest Society (IRIS). IRIS Staging of CKD. IRIS website. [www.iris-kidney.com/guidelines/staging.html](http://www.iris-kidney.com/guidelines/staging.html). Accessed December 6, 2024.

# Staging CKD using IRIS guidelines



		Stage 1 No azotemia (Normal creatinine)	Stage 2 Mild azotemia (Normal or mildly elevated creatinine)	Stage 3 Moderate azotemia	Stage 4 Severe azotemia
<b>Creatinine in mg/dL</b> <small>Stage based on stable creatinine</small>	Canine	Less than 1.4 (125 µmol/L)	1.4–2.8 (125–250 µmol/L)	2.9–5.0 (251–440 µmol/L)	Greater than 5.0 (440 µmol/L)
	Feline	Less than 1.6 (140 µmol/L)	1.6–2.8 (140–250 µmol/L)	2.9–5.0 (251–440 µmol/L)	Greater than 5.0 (440 µmol/L)
<b>SDMA* in µg/dL</b> <small>Stage based on stable SDMA</small>	Canine	Less than 18	18–35	36–54	Greater than 54
	Feline	Less than 18	18–25	26–38	Greater than 38
<b>UPC ratio</b> <small>Stage based on stable proteinuria</small>	Canine	Nonproteinuric < 0.2    Borderline proteinuric 0.2–0.5    Proteinuric > 0.5			
	Feline	Nonproteinuric < 0.2    Borderline proteinuric 0.2–0.4    Proteinuric > 0.4			
<b>Systolic blood pressure in mm Hg</b> <small>Substage based on blood pressure</small>		Normotensive < 140    Prehypertensive 140–159 Hypertensive 160–179    Severely hypertensive ≥ 180			

Familiar biomarkers aid in staging

SDMA provides an earlier window into changes in GFR

Urine protein:creatinine (UPC) ratio strengthens findings beyond urine specific gravity (USG)

Systolic blood pressure may indicate need for additional intervention

**Note:** In the case of staging discrepancy between creatinine and SDMA, consider patient muscle mass and retesting both in 2–4 weeks. If values are persistently discordant, consider assigning the patient to the higher stage.

\*SDMA = IDEXX SDMA® Test result

See [www.iris-kidney.com](http://www.iris-kidney.com) for more detailed staging, therapeutic, and management guidelines.

# Treatment of CKD using IRIS guidelines



## Treatment recommendations

	Stage 1	Stage 2	Stage 3	Stage 4
	Use nephrotoxic drugs with caution	Same as Stage 1	Same as Stage 2	Same as Stage 3
	Correct prerenal and postrenal abnormalities	Renal therapeutic diet	Keep phosphorus < 5.0 mg/dL (< 1.6 mmol/L)	Keep phosphorus < 6.0 mg/dL (< 1.9 mmol/L)
	Fresh water available at all times	Treat hypokalemia in cats	Treat metabolic acidosis	Consider feeding tube for nutritional and hydration support and ease of medicating
	Monitor trends in creatinine and SDMA to document stability or progression	Treat inappetence and nausea if present	Consider treatment of anemia	
	Investigate for and treat underlying disease and/or complications		Treat vomiting, inappetence, and nausea	
	Treat hypertension if systolic blood pressure persistently > 160 or evidence of end-organ damage		Increased enteral or subcutaneous fluids may be required to maintain hydration	
	Treat persistent proteinuria with renal therapeutic diet and medication			
	Keep phosphorus < 4.6 mg/dL (< 1.5 mmol/L)			
	If required, use renal therapeutic diet plus phosphate binder			


Routine chemistry monitoring including SDMA, urinalysis, and UPC ratio

FGF-23 in **cats** with IRIS CKD Stages 1 and 2

# Regulation of phosphorus in CKD

## Hyperphosphatemia

- + Other relevant players: phosphatonins
- + Fibroblast growth factor 23 (FGF-23)
- + Released from osteocytes in response to increased phosphorus, calcitriol, and PTH concentrations
- + Decreases phosphorus and calcitriol concentrations



**Source:** Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. *Nat Rev Endocrinol.* 2009;5(11):611–619. doi:10.1038/nrendo.2009.196

# Chronic kidney disease–mineral bone disorder (CKD-MBD)



Decreased GFR

Reduced phosphorus excretion

Calcium–phosphorus imbalance


CKD-MBD

# CKD-MBD

## Hyperphosphatemia

One of the most important risk factors for CKD progression of disease and survival in cats and dogs

- + Reduced phosphate excretion in CKD → CKD-MBD
  - + Abnormalities of calcium-phosphate homeostasis, bone disease, and soft tissue calcification
    - + Renal secondary hyperparathyroidism
    - + Accelerated progression of CKD
    - + Increased mortality rate
    - + Renal osteodystrophy
    - + Extraskkeletal calcification
    - + Hypo- or hypercalcemia, and hypo- or hypermagnesaemia




# FGF-23

Cats diagnosed with  
**IRIS CKD Stage 1 or 2**

Phosphorus < 4.6 mg/dL  
(1.5 mmol/L)

📄 📄 IDEXX SDMA	a. 19	0 - 14 µg/dL	
📄 📄 Creatinine	2.0	0.9 - 2.5 mg/dL	
📄 📄 BUN	34	16 - 37 mg/dL	
📄 BUN: Creatinine Ratio	17.0		
📄 📄 Phosphorus	3.7	2.9 - 6.3 mg/dL	





Homeostasis

- + Phosphorus
- + Parathyroid hormone (PTH)
- + Calcium
- + 1,25-dihydroxycholecalciferol (vitamin D)


**FGF-23 increases before overt hyperphosphataemia** providing an opportunity for therapeutic intervention to **interrupt the progression of CKD-MBD**

# FGF-23 identifies phosphorus overload before overt hyperphosphataemia





# Algorithm: Identifying and managing phosphorus overload in cats diagnosed with CKD




# FGF-23 fills a diagnostic gap for when to institute a therapeutic kidney diet in CKD for cats

## FGF-23


### Diagnosing CKD

SDMA  
Creatinine  
Phosphorus  
Urinalysis



### Management marker


Is diet change warranted?  
  
Which diet is appropriate?  
  
Are my treatment choices helping?



### Treatment and monitoring

Diet  
Medication  
Rechecks

Active/acute kidney injury



# Potential causes of AKI


## Prerenal

- Decreased perfusion
- + **Hypovolaemia**
- + **Dehydration**
- + Heart disease
- + Liver disease
- + NSAIDs/ACEIs
- + Other




## Intrarenal

- + **Tubular** disease
  - + Acute tubular necrosis (ATN)
    - + Toxic
    - + Ischemic
- + **Glomerular** disease
  - + Primary immune
  - + Secondary immune
  - + Amyloid
- + **Interstitial**
  - + Acute interstitial nephritis
  - + Drug
  - + Infectious
- + **Vascular** disease





## Postrenal

- + Leak in urinary tract
  - + **Obstructive**
    - + Stones
    - + Mass
    - + Blood clot
    - + Prostatic disease
    - + Other





# Mechanisms for pathogenesis of AKI in cats and dogs

## Etiologies of AKI



**Tubular damage—Acute tubular necrosis (ATN) is the term used to designate AKI resulting from damage to the tubules.**




# Stages of AKI

Healthy

1. Initiation

2. Extension

3. Maintenance



**Healthy tubular epithelium:**  
Normal urine output

**Initial insult:**  
Cellular damage/death  
Urine output may be unchanged





**Progressive swelling with or without death of epithelial cells:**  
Oligoanuria possible

**Cell lysis/sloughing**  
**Debris occluding tubule**  
**Back leak** and inflammation  
Oligoanuria

Courtesy of Dr. Sherri Ross

© 2025 IDEXX Laboratories, Inc. All rights reserved.

# 4. Recovery (hopefully)





**Sad renal tubule**  
If basement membrane intact, recovery possible

**Cell regeneration begins**  
Some function returns

**Tubular epithelial cells mature**  
Varying return of function

Courtesy of Dr. Sherri Ross

# Cystatin B is a very small protein that is contained in the epithelial cells of the renal tubules





## References

1. Hall JA, Yerramilli M, Obare E, Yerramilli M, Yu S, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in healthy geriatric cats fed reduced protein foods enriched with fish oil, L-carnitine, and medium-chain triglycerides. *Vet J.* 2014;202(3):588–596. doi:10.1016/j.tvjl.2014.10.021
2. Hall JA, Yerramilli M, Obare E, Yerramilli M, Almes K, Jewell DE. Serum concentrations of symmetric dimethylarginine and creatinine in dogs with naturally occurring chronic kidney disease. *J Vet Intern Med.* 2016;30(3):794–802. doi:10.1111/jvim.13942
3. Hall JA, Yerramilli M, Obare E, Yerramilli M, Jewell DE. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. *J Vet Intern Med.* 2014;28(6):1676–1683. doi:10.1111/jvim.12445
4. Nabyt MB, Lees GE, Boggess MM, et al. Symmetric dimethylarginine assay validation, stability, and evaluation as a marker for the early detection of chronic kidney disease in dogs. *J Vet Intern Med.* 2015;29(4):1036–1044. doi:10.1111/jvim.12835




During active or acute injury to the kidney, the cells that line the tubules can become damaged or necrotic



**Increased cystatin B** can occur with or without functional marker increase, **alerting to earlier, ongoing, and unresolved** injury to the kidney.

# The types of active and acute injury that can cause cystatin B to leak into urine include both primary and secondary insults to the kidney



1

- + Primary nephritis (GN or pyelonephritis)
- + Immune-mediated disease
- + Chronic kidney disease (CKD)

2

- + Toxic insult
- + Systemic inflammatory disease (pancreatitis, vasculitis, other shock-related conditions)
- + Hypotension during anesthesia
- + Hypovolemia (blood loss)

# The IDEXX Cystatin B Test

## Novel kidney injury marker

- + Urine-based test
- + Cystatin B is very stable within urine when refrigerated/stored properly\*
- + Indicated for use on unwell dogs and cats
- + Available from IDEXX Reference Laboratories and with IDEXX Anywhere Urinalysis with SediVue Dx<sup>®</sup> Urine Sediment Analyzer codes



\*Stable for up to 7 days at 4°C and 3 days at 30°C.

# When to use Examples

## Use case


- + Veterinarian suspects a toxin exposure and is looking to confirm active injury
- + Monitoring treatment/recovery from an injury event
- + Dogs with IRIS CKD Stage 1
- + Patients that may be at higher risk when taking an NSAID
- + Shock (heat stroke, acute pancreatitis)
- + Anesthetic hypotensive event

## Potential action

- + Confidence that treatment course is the correct one
- + Feedback that treatment is working or not; is the insult ongoing?
- + IDEXX Cystatin B Test can provide indication of CKD progression; if disease is progressing, consider more aggressive treatment
- + If ongoing injury is occurring, consider NSAID alternatives
- + Assess if injury occurred/is ongoing to determine next steps
- + Assess if injury occurred/is ongoing to determine next steps



# Renal health in the sick pet




## Emergent cases

- + Vehicular trauma
- + Hemoabdomen
- + Gastric dilatation and volvulus (GDV)
- + Uroabdomen
- + Toxin exposure
- + Seizures
- + Hyperthermia

## Hospitalised patients

- + Post-op hospitalisation
- + Sick diabetic
- + Addisonian crisis
- + Pancreatitis
- + Urethral obstruction

# Kidney's role in renal monitoring in the sick pet



1

## GDV

- + AKI as a significant risk factor for death<sup>1</sup>

2

## Toxin exposure

- + Lilies (cats)
- + Ethylene glycol
- + NSAIDs
- + Aminoglycosides

3

## Pyometra

- + Azotaemia/renal dysfunction<sup>2</sup>
- + Proteinuria<sup>2</sup>

4

## Hyperthermia

- + Renal tubular necrosis<sup>3</sup>

5

## Hospitalised patients

- + Postoperative
- + Diabetic ketoacidosis (DKA)
- + Addisonian crisis
- + Pancreatitis

### References

1. Sharp CR, Rozanski EA. Cardiovascular and systemic effects of gastric dilatation and volvulus in dogs. *Top Companion Anim Med.* 2014;29(3):67–70. doi:10.1053/j.tcam.2014.09.007
2. Maddens B, Heiene R, Smets P, et al. Evaluation of kidney injury in dogs with pyometra based on proteinuria, renal histomorphology, and urinary biomarkers. *J Vet Intern Med.* 2011;25(5):1075–1083. doi:10.1111/j.1939-1676.2011.0772.x
3. Stern A. Canine environmental hyperthermia: a case series. *J Vet Med Sci.* 2019;81(2):190–192. doi:10.1292/jvms.18-0586

# IDEXX Cystatin B Test: interpreting normal results

Cystatin B < 100 ng/mL  
There is a decreased potential of kidney injury

SDMA or creatinine  
within reference intervals  
Appropriately concentrated urine


Evidence of renal injury not present  
at this time

SDMA or creatinine  
outside reference intervals  
Inappropriately concentrated urine

Previous history of kidney disease



# IDEXX Cystatin B Test: interpreting increased results





[Home](#)
[Directory of Services](#)
[Imaging](#)
[Telemedicine](#)

---

**BELLA FITZPATRICK** 203AB [Patient Management](#)

Canine | Mixed Breed | Female | 8y

2023 **Dec 21** 2024 NOV 4

[Result details](#)

Chemistry	12/21/23 5:13 AM		11/2/22 6:32 AM
Glucose	92	63 - 114 mg/dL	88
IDEXX SDMA	7	0 - 14 µg/dL	15
Creatinine	1.4	0.5 - 1.5 mg/dL	1.2
BUN	14	9 - 31 mg/dL	13
IDEXX Cystatin B (Urine)	65	0 - 99 ng/mL	

[Learn More](#)

**The IDEXX Cystatin B Test**

Detects a urinary kidney marker that indicates active and/or acute injury caused by current and ongoing insult. It is best performed on sick patients or patients with known kidney disease.

**Introducing IDEXX Cystatin B**

With the IDEXX Cystatin B Test, IDEXX's kidney health suite is more comprehensive than ever. Never before have veterinarians been able to detect active or acute injury to the kidneys with a kidney injury marker. Now with the IDEXX

9:41

**Bella Fitzpatrick**

8 y • Female • Mixed Breed • Canine

[Report](#)
[Graph](#)
[Differential](#)

New! Learn more about Cystatin B

**Chemistry**

12/21/2023 ID

Glucose	92 mg/dL
IDEXX SDMA	7 µg/dL
Creatinine	1.4 mg/dL
BUN	14 mg/dL
IDEXX Cystatin B (Urine)	65 ng/mL
BUN:Creatinine Ratio	10.0
Total Protein	5.6 g/dL
Albumin	3.2 g/dL

9:41

[Differential](#)
[Result values](#)
[Result note](#)

**The IDEXX Cystatin B Test**

Detects a urinary kidney marker that indicates active and/or acute injury caused by current and ongoing insult. It is best performed on sick patients or patients with known kidney disease.

**Introducing IDEXX Cystatin B**

With the IDEXX Cystatin B Test, IDEXX's kidney health suite is more comprehensive than ever. Never before have veterinarians been able to detect

Cystatin B  $\geq$  100 ng/mL:  
There is an increased  
potential of active  
kidney injury

- + Injury MAY RESOLVE
- + Injury may NOT be permanent
- + Consider ALL factors including
  - + Age
  - + Breed
  - + History

Patient presented  
for wellness visit

SDMA and  
creatinine within  
reference intervals

Appropriately  
concentrated  
urine

**Possible** subclinical kidney injury

In a well patient, subclinical kidney injury  
cannot be ruled out

Subclinical kidney injury may be caused by  
a single acute inciting event and may not  
result in overt clinical signs or changes in  
functional markers

**A comprehensive history**, such as diet,  
medications, supplements, preventives,  
travel, and other information, should be  
obtained.

**Consider** rechecking cystatin B and other  
kidney markers, including SDMA, in 1–2  
weeks or sooner if clinical signs become  
apparent

# Traditional diagnostics only allow for case evaluation by functional markers

High/Abnormal




Toxin exposure



Progressive CKD



Stable CKD



Anesthetic hypotensive event

Chronic NSAID use

Healthy

**Functional Markers**


SDMA  
Creatinine  
BUN

Low/Normal


# Addition of an injury marker provides better case discrimination and management

High/Abnormal


Functional Markers  
SDMA  
Creatinine  
BUN



# Diverse renal health portfolio



Questions?



**IDEXX**